Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles

NCT ID: NCT01212809

Last Updated: 2011-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-09-30
• Study Completion Date: 2011-06-30

Brief Summary

This study is being done to evaluate the differences in the performance of two well known injectable dermal fillers commonly used for the cosmetic treatment of age lines above the lips and on the cheeks when compared to each other in the same patient. The products being tested are Juvéderm® Ultra and CosmoDerm® 1.

Detailed Description

This is a single center, prospective, open label, randomized, comparative, split-face study in adult females or males aged 25 to 70 years seeking treatment with reconstituted Juvéderm® Ultra and CosmoDerm® 1 human-based collagen implant for moderate to severe vertical lip rhytids and/or radial cheek lines.

Conditions

Intrinsic Aging of Skin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Juvéderm Ultra

Juvéderm Ultra injection

Group Type: ACTIVE_COMPARATOR

Juvéderm Ultra

Intervention Type: DEVICE

Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face

Cosmoderm 1

Cosmoderm 1 injection

Group Type: ACTIVE_COMPARATOR

Cosmoderm 1

Intervention Type: DEVICE

Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face

Interventions

Juvéderm Ultra

Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face

Intervention Type: DEVICE

Cosmoderm 1

Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face

Intervention Type: DEVICE

Other Intervention Names

Juvéderm Ultra injectable gel (crosslinked hyaluronic acid); Cosmoderm 1 human-based collagen implant

Eligibility Criteria

Inclusion Criteria

• Adult females or males, aged 25 to 70 years;
• Subjects must be seeking treatment with Juvéderm Ultra and CosmoDerm 1 injections for vertical lip rhytids or radial cheek lines;
• Subjects must have one or more moderate to severe vertical lip rhytids and/or moderate to severe radial cheek lines based on the physician evaluator assessment (0-3 scale);
• Women must either be of non-childbearing potential (i.e., surgically sterilized or post-menopausal) or if of childbearing potential, must not be pregnant (as documented by a negative urine pregnancy test at the baseline examination) or lactating and must be practicing a medically acceptable method of birth control;
• Subjects must be willing and able to provide written informed consent;
• Subjects must be willing and able to follow the procedures outlined in this protocol.

Exclusion Criteria

• Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control;
• Previous Botox treatment to the lower two-thirds of the face within the past 6 months for subjects who will have injections into their radial cheek lines. Note: this exclusion criterion does not apply to subjects who only will have injections into lip rhytids unless the previous Botox treatment was administered within the past 6 months to the upper lip region;
• Previous semipermanent injectable filler therapy to the mid-lower face within the past year or any prior history of permanent filler therapy injection to the mid-lower face;
• Prior cosmetic procedures (i.e., facelift, etc.) or visible scars that may affect evaluation of response and/or quality of photography in the opinion of the investigator;
• Known allergy or sensitivity to any of the treatment injections or their components, including known or suspected lidocaine hypersensitivity;
• Known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies;
• Subjects with an infection at an injection site or systemic infection (in this case, postpone study entry until one week following recovery);
• Subjects requiring treatment with major anticoagulants (such as Coumadin) or antiplatelets (such as Plavix) during the study; low-dose aspirin treatment or antiinflammatory medication with potential anticoagulant or antiplatelet effect may be allowed at the investigator's discretion;
• Concurrent participation in an investigational drug or device study or participation within 30 days of study start;
• Subjects are not to undergo any additional cosmetic procedures during the study period;
• Subjects are not to change use of any facial products up to 6 months prior to enrollment and during study period;
• Subjects with a history of poor cooperation, non-compliance with medical treatment, or unreliability.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Steven Fagien

OTHER

Sponsor Role: lead

Responsible Party

Steven Fagien

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Steven Fagien, MD

Role: PRINCIPAL_INVESTIGATOR

Steven Fagien, MD, PA

Locations

Steven Fagien, MD, PA

Boca Raton, Florida, United States

Countries

United States

Other Identifiers

JUVE_COSMO_1-10-01

Identifier Type: -

Identifier Source: org_study_id